Urcosimod Phase 2a Trial Shows Meaningful QoL Improvements in Neuropathic Corneal Pain
OKYO sits 55% above its 52-week low of $1.03.
Summary
OKYO Pharma announced new positive exploratory Phase 2a data for its drug candidate, Urcosimod, in treating neuropathic corneal pain (NCP). The data demonstrated meaningful improvements in patient-reported quality of life (QoL) outcomes, including emotional well-being and daily life satisfaction, compared to placebo. This builds on previously reported primary efficacy signals (pain reduction) from the same small Phase 2a trial. NCP is a severe condition with no FDA-approved treatments, representing a significant unmet medical need. While the data is from an exploratory analysis of a small trial (n=6 per arm), these positive QoL findings, alongside pain reduction, suggest a broader therapeutic profile for Urcosimod and strengthen the case for its advancement. The company plans confirmatory studies, including a larger multi-center Phase 2b/3 trial, which will be critical for validating these encouraging early results.
At the time of this announcement, OKYO was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82.2M. The 52-week trading range was $1.03 to $3.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.